Publications by authors named "David Calvin"

Claim this Profile
D
Diagnostic and therapeutic challenge of neuroendocrine endometrial carcinoma: a case report.
Hariyono Winarto, David Calvin, Fitriyadi Kusuma, Kartiwa Hadi Nuryanto, Yuri Feharsal

Pan Afr Med J· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic Challenge: Distinguishing Uterine Fibroid with Cystic Degeneration vs. Ovarian Cystic Malignancy. A Case Report.
Hariyono Winarto, Octaviyana Nadia Nitasari Simatupang, David Calvin, Trifonia Pingkan Siregar, Andrijono

J Radiol Case Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Hepatocellular Carcinoma: Transplantation versus Resection: The Case for Liver Resection.
Nishant Merchant, Calvin S David, Steven C Cunningham

Int J Hepatol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azetidine-based inhibitors of dipeptidyl peptidase IV (DPP IV).
Dana Ferraris, Sergei Belyakov, Weixing Li, Eddie Oliver, Yao-Sen Ko, David Calvin

Curr Top Med Chem· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy.
Ajit G Thomas, Krystyna M Wozniak, Takashi Tsukamoto, David Calvin, Ying Wu

Adv Exp Med Biol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enantiospecificity of glutamate carboxypeptidase II inhibition.
Takashi Tsukamoto, Pavel Majer, Dilrukshi Vitharana, Chiyou Ni, Bunda Hin, David C Calvin

J Med Chem· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.
Lucio Tentori, Carlo Leonetti, Marco Scarsella, Matteo Vergati, Weizheng Xu, David Calvin

Int J Oncol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors.
Dana Ferraris, Yao-Sen Ko, David Calvin, Tiffany Chiou, Susan Lautar

Bioorg Med Chem Lett· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pearls.
Calvin P David, Rochelle Taube, Robert M Glazer, Joseph K Askinasi

Phys Sportsmed· May 1994

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis